Is PCRX or PCSA more undervalued in 2026?

CirclFi compares Pacira BioSciences, Inc. (PCRX) and Processa Pharmaceuticals, Inc. (PCSA) using 13 institutional-grade valuation models. PCRX has a Quality of Company score of 8.7/10 while PCSA scores 3.7/10.

Which is a better buy — PCRX or PCSA?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PCRX and PCSA valuations compare?

PCRX at $23.22 and PCSA at $2.56 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PCRX vs PCSA Valuation Comparison 2026 — Intrinsic Value Analysis

PCRX

Pharmaceutical Preparations

Pacira BioSciences, Inc.

Quality

8.7

out of 10

Value Trap

SAFE

Price

$23.22

Last close

Models

13/13

Active

PCSA

Pharmaceutical Preparations

Processa Pharmaceuticals, Inc.

Quality

3.7

out of 10

Value Trap

SAFE

Price

$2.56

Last close

Models

7/13

Active

Model-by-Model Comparison

Model	Type	PCRX Fair Value	PCRX Upside	PCSA Fair Value	PCSA Upside
Bayesian DCF	Intrinsic	$60.00	+158.4%	$1.05	-59.2%
Earnings Power Value	Intrinsic	$33.57	+44.6%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$10.92	-53.0%	$0.20	-93.4%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PCRX vs PCSA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PCRX vs PCSA — Which Stock Is More Undervalued?

PCRX scores higher with a 8.7/10 quality rating vs PCSA's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pacira BioSciences, Inc. (PCRX) and Processa Pharmaceuticals, Inc. (PCSA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PCRX currently trades at $23.22 with a QOC of 8.7/10, while PCSA trades at $2.56 with a QOC of 3.7/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).